Can Intuitive Surgical’s Revenue Grow in 2017?
Intuitive Surgical’s revenue estimates
On July 20, 2017, Intuitive Surgical (ISRG) will announce its 2Q17 earnings. The company has exceeded analysts’ revenue estimates for the last several quarters. The graph below shows analysts’ revenue estimates and the company’s actual reported revenues.
Interested in ISRG? Don't miss the next report.
Receive e-mail alerts for new research on ISRG
In 2Q17, Wall Street estimates that the company will report around $721.3 million in revenues. The estimate represents a rise of ~7.6% on a YoY (year-over-year) basis.
In 1Q17, Intuitive Surgical reported revenues of ~$674.2 million. The company’s actual revenues exceeded analysts’ expectations mainly driven by the strong momentum in system placements and robust procedure growth. International placements contributed strongly to the company’s revenues. US capital placements, however, saw moderate growth.
TransEnterix (TRXC), Medtronic (MDT), and Verb Surgical, which is a joint venture of Alphabet (GOOGL) and Johnson & Johnson (JNJ), pose competitive threats to Intuitive Surgical, as the companies are developing technologies to enter the robotics surgery market. Transenterix’s SurgiBot system is a competing product that the company expects to offer at a lower price than ISRG’s da Vinci. However, the FDA rejected the Transenterix’s Surgibot approval application in 2016, and the company has since shifted its focus to its other robotics system. For more detail, read Competition in the Robotics Surgical Space Impacts Intuitive Surgical.
Investors seeking diversified exposure to Intuitive Surgical can consider investing in the iShares Core S&P 500 ETF (IVV). ISRG accounts for ~0.17% of the total holdings of IVV.
Next, let’s discuss Intuitive Surgical’s 2Q17 earnings estimates.